Cite
HARVARD Citation
Savona, M. et al. (n.d.). 60 EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE. Leukemia research. 39 (1), pp. S29-S30. [Online].